Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 619 results
Found 619 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Erlandson KM, Taejaroenkul S, Smeaton L, et al. "A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings." Open Forum Infect Dis. 2015;2(3):ofv095.
Erlandson KM, Kitch D, Tierney C, et al. "Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density." AIDS. 2013;27(13):2069-79.
Eron JJ, Park J-G, Haubrich R, et al. "Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy." Antimicrob. Agents Chemother.. 2009;53(6):2335-41.
Eron JJ, Bosch RJ, Bettendorf D, Petch L, Fiscus S, Frank I. "The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine." J. Acquir. Immune Defic. Syndr.. 2007;45(2):249-51.
Eshleman SH, Hudelson SE, Redd AD, et al. "Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial." J. Infect. Dis.. 2011;204(12):1918-26.
Evans SR, Fichtenbaum CJ, Aberg JA. "Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087." HIV Clin Trials. 2007;8(1):45-52.
Evans SR, Clifford DB, Kitch DW, et al. "Simplification of the research diagnosis of HIV-associated sensory neuropathy." HIV Clin Trials. 2008;9(6):434-9.
Evans SR, Simpson DM, Kitch DW, et al. "A randomized trial evaluating Prosaptide for HIV-associated sensory neuropathies: use of an electronic diary to record neuropathic pain." PLoS ONE. 2007;2(6):e551.
Evans SR, Yeh T-min, Sacktor N, et al. "Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090." HIV Clin Trials. 2007;8(6):437-46.
Evans SR, Ellis RJ, Chen H, et al. "Peripheral neuropathy in HIV: prevalence and risk factors." AIDS. 2011;25(7):919-28.
Evans SR, Lee AJ, Ellis RJ, et al. "HIV peripheral neuropathy progression: protection with glucose-lowering drugs?" J. Neurovirol.. 2012;18(5):428-33.


Ferreira MAR, Mangino M, Brumme CJ, et al. "Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control." Am. J. Hum. Genet.. 2010;86(1):88-92.
Fichtenbaum CJ, Yeh T-min, Evans SR, Aberg JA. "Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087." J Clin Lipidol. 2010;4(4):279-87.
Fichtenbaum CJ, Evans SE, Aberg JA. "High-sensitivity C-reactive protein levels do not decrease with the use of statins in all persons with HIV infection." AIDS. 2011;25(16):2053.
Fife KH, Wu JW, Squires KE, D Watts H, Andersen JW, Brown DR. "Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2009;51(3):274-82.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Firnhaber C, Smeaton L, Saukila N, et al. "Comparisons of anemia, thrombocytopenia, and neutropenia at initiation of HIV antiretroviral therapy in Africa, Asia, and the Americas." Int. J. Infect. Dis.. 2010;14(12):e1088-92.
Fischl MA, Collier AC, A Mukherjee L, et al. "Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen." AIDS. 2007;21(3):325-33.
Fiscus SA, Cu-Uvin S, Eshete ATilahun, et al. "Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy." Clin. Infect. Dis.. 2013;57(2):290-7.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Flexner C, Tierney C, Gross R, et al. "Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial." Clin. Infect. Dis.. 2010;50(7):1041-52.
Foulkes AS, Wohl DA, Frank I, et al. "Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy." PLoS Med.. 2006;3(3):e52.
Foulkes AS, DeGruttola VG. "A resampling-based approach to multiple testing with uncertainty in phase." Int J Biostat. 2007;3(1):Article 2.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. "Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis." PLoS ONE. 2008;3(4):e1915.
Funderburg N, Lederman MM, Feng Z, et al. "Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2." Proc. Natl. Acad. Sci. U.S.A.. 2007;104(47):18631-5.